NASDAQ:ICCC ImmuCell (ICCC) Stock Price, News & Analysis → Musk’s new company could top a trillion? (From Paradigm Press) (Ad) Free ICCC Stock Alerts $4.18 -0.03 (-0.71%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$4.15▼$4.2050-Day Range$4.18▼$5.4852-Week Range$4.15▼$6.02Volume5,489 shsAverage Volume12,371 shsMarket Capitalization$32.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get ImmuCell alerts: Email Address Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About ImmuCell Stock (NASDAQ:ICCC)ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Read More ICCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICCC Stock News HeadlinesJune 5, 2024 | globenewswire.comImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®June 4, 2024 | globenewswire.comImmuCell to Hold Virtual-Only Annual Meeting of StockholdersMay 16, 2024 | insidermonkey.comImmuCell Corporation (NASDAQ:ICCC) Q1 2024 Earnings Call TranscriptMay 15, 2024 | seekingalpha.comImmuCell Corporation (ICCC) Q1 2024 Earnings Call TranscriptMay 14, 2024 | investorplace.comICCC Stock Earnings: ImmuCell Reported Results for Q1 2024May 14, 2024 | globenewswire.comImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024May 8, 2024 | globenewswire.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024April 10, 2024 | finanznachrichten.deImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024April 9, 2024 | msn.comImmuCell reports preliminary Q1 sales, stock climbs 7%April 9, 2024 | markets.businessinsider.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024April 9, 2024 | globenewswire.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024February 29, 2024 | finance.yahoo.comImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | seekingalpha.comImmuCell Corporation (ICCC) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | globenewswire.comImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023February 16, 2024 | finance.yahoo.comImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023February 16, 2024 | globenewswire.comImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023January 9, 2024 | benzinga.comImmuCell Stock (NASDAQ:ICCC) Dividends: History, Yield and DatesJanuary 9, 2024 | finanznachrichten.deImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023January 8, 2024 | msn.comImmuCell says total sale for year ended December falls 6% Y/YJanuary 8, 2024 | finance.yahoo.comImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023November 15, 2023 | finance.yahoo.comImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | seekingalpha.comImmuCell Corporation (ICCC) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | msn.comImmuCell GAAP EPS of -$0.12, revenue of $5.39MNovember 13, 2023 | finance.yahoo.comImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023November 7, 2023 | finance.yahoo.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023See More Headlines Receive ICCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/15/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:ICCC CUSIPN/A CIK811641 Webwww.immucell.com Phone(207) 878-2770Fax207-878-2117Employees74Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,780,000.00 Net Margins-18.31% Pretax Margin-18.29% Return on Equity-15.21% Return on Assets-8.89% Debt Debt-to-Equity Ratio0.41 Current Ratio2.71 Quick Ratio1.00 Sales & Book Value Annual Sales$17.47 million Price / Sales1.87 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book1.29Miscellaneous Outstanding Shares7,810,000Free Float7,296,000Market Cap$32.65 million OptionableNot Optionable Beta0.57 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Michael F. Brigham (Age 63)President, CEO, Principal Financial Officer, Treasurer, Secretary & Director Comp: $395.24kMs. Bobbi Jo Brockmann (Age 47)VP of Sales & Marketing and Director Comp: $323.52kElizabeth S. ToothakerDirector of Finance & Administration and ControllerMr. A. Gustavo ScaffaSenior Director of QualityJohn W. ZinckgrafDirector of Product DevelopmentKey CompetitorsAlpha TeknovaNASDAQ:TKNOVolitionRxNYSE:VNRXARCA biopharmaNASDAQ:ABIOAspira Women's HealthNASDAQ:AWHOncoCyteNASDAQ:OCXView All CompetitorsInstitutional OwnershipMesirow Financial Investment Management Inc.Bought 12,178 shares on 4/26/2024Ownership: 0.157%View All Institutional Transactions ICCC Stock Analysis - Frequently Asked Questions How have ICCC shares performed in 2024? ImmuCell's stock was trading at $5.09 at the start of the year. Since then, ICCC shares have decreased by 17.9% and is now trading at $4.18. View the best growth stocks for 2024 here. Are investors shorting ImmuCell? ImmuCell saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 5,000 shares, an increase of 66.7% from the May 15th total of 3,000 shares. Based on an average trading volume of 11,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's shares are short sold. View ImmuCell's Short Interest. When is ImmuCell's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ICCC earnings forecast. How were ImmuCell's earnings last quarter? ImmuCell Co. (NASDAQ:ICCC) released its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.06) earnings per share for the quarter. The biotechnology company earned $7.26 million during the quarter. ImmuCell had a negative net margin of 18.31% and a negative trailing twelve-month return on equity of 15.21%. What guidance has ImmuCell issued on next quarter's earnings? ImmuCell issued an update on its first quarter 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.3 million-$7.3 million. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE). Who are ImmuCell's major shareholders? ImmuCell's stock is owned by a variety of institutional and retail investors. Top institutional investors include Mesirow Financial Investment Management Inc. (0.16%). View institutional ownership trends. How do I buy shares of ImmuCell? Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ICCC) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.